Need professional-grade analysis? Visit stockanalysis.com
$18.01M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
LianBio (LIANY) Price Performance
LianBio (LIANY) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $0.17, up 3.03% from the previous close.
Over the past year, LIANY has traded between a low of $0.04 and a high of $0.43. The stock has lost 14.1% over this period. It is currently 60.7% below its 52-week high.
LianBio has a market capitalization of $18.01M.
About LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-105,259,000
- Profit Margin
- N/A
- EPS (TTM)
- -2.07
- Book Value
- 1.89
Technical Indicators
- 52 Week High
- $0.44
- 52 Week Low
- $0.03
- 50 Day MA
- $0.10
- 200 Day MA
- $0.13
- Beta
- 0.42
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -0.46
- Price/Sales
- N/A
- Price/Book
- 0.09
- Enterprise Value
- $-197,774,672